Back to Research

Organization profile

NovaGo Therapeutics

NovaGo Therapeutics is a Swiss biotechnology company that develops regenerative antibody therapies to repair traumatic injuries of the central nervous system. Its lead program focuses on blocking Nogo-A, a potent nerve growth inhibitor, to stimulate axon regeneration and restore functional movement in patients with acute spinal cord injury.

Schlieren, SwitzerlandFounded 2015

Overview

1. Executive Summary (Confidence: High)

Founded in 2015 as a spin-off from the University of Zurich, NovaGo Therapeutics is a pioneer in the field of neuro-regeneration.[18] The company’s core strategy revolves around its lead drug candidate, NG004, a human monoclonal antibody currently in a First-in-human (FIH) Phase 1b trial known as "SPROUT".[20] NovaGo addresses a critical unmet medical need: the restoration of motor and sensory function after spinal cord injury (SCI), for which no effective restorative therapy currently exists.[19] By leveraging a strategic partnership with Neurimmune AG for antibody discovery, NovaGo has developed a high-affinity therapy that targets the biological "brakes" on nerve growth, aiming to transform SCI from a permanent disability into a treatable condition.[18]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.